USA VC Funds

Anthem Venture Partners, founded in 2000 and based in Santa Monica, California, is a venture capital firm specializing in early-stage Series A and B investments. The firm primarily focuses on technology companies in Southern California, investing in sectors like software, internet, semiconductors, and new media​. Anthem typically invests between $1 million to $5 million in its portfolio companies and often takes a board seat, indicating a hands-on approach. The firm aims to be the first institutional investor, leading or co-leading the investments. Notable investments by Anthem Venture Partners include Surf Air, indie Semiconductor, Scopely, and Bird Global. The firm has a track record of successful exits, such as the IPO of Surf Air Mobility and the acquisition of Scopely by Savvy Games Group for $4.9 billion​. The team is led by founder and Managing General Partner William Woodward, along with partners like Claudia Llanos and Entrepreneur-in-Residence Sudhin Shahani. The firm's philosophy emphasizes building strong relationships with founders and taking a personal stake in the success of each investment​.

Anthemis Group, founded in 2010 and headquartered in London, is a global investment platform dedicated to fostering innovation in the financial system. The firm focuses on fintech, insurtech, and related sectors, investing from seed to growth stages. Anthemis' portfolio includes notable companies such as Betterment, eToro, and Currencycloud. They also back innovative startups like Pipe, Weavr, and Atomic. With over 150 investments worldwide, Anthemis emphasizes diversity and inclusivity, with 23% of their portfolio companies founded by women and 40% led by women or BIPOC. Their commitment to diversity is further demonstrated through the Female Innovators Lab, which supports female founders in fintech across the UK and Europe. Anthemis recently closed multiple funds totaling over $700 million, expanding their support for fintech companies throughout their lifecycle. The firm also launched an ESG-focused SPAC to advance sustainable finance. Anthemis' thesis-driven approach leverages deep market insights to drive systemic, long-term change. Led by founder Amy Nauiokas and CEO Briana van Strijp, Anthemis is poised to continue its mission of reinventing finance through innovation, collaboration, and inclusivity, supporting the next wave of fintech innovation globally.

Anthos Capital, founded in 2007 and based in Santa Monica, California, focuses on growth-stage investments in consumer products, technology, healthcare, and financial services sectors. The firm has made notable investments in companies like Carbon Robotics, known for its Autonomous Weeder which helps reduce reliance on herbicides, and Todyl, a comprehensive cybersecurity platform aimed at small and mid-market businesses. Anthos Capital takes a strategic partnership approach, providing not just capital but also operational and strategic support to help portfolio companies grow and lead their industries. They focus on investments that promise significant growth and impact, supporting companies from early to growth stages with tailored assistance. The firm's recent investment activities include significant funding rounds for companies like Carbon Robotics and Todyl, reflecting their commitment to fostering innovation and industry leadership. Their portfolio showcases a diverse range of companies, emphasizing Anthos Capital's ability to identify and nurture high-potential ventures across various sectors.

Anti Fund, launched in 2021 by Jake Paul and Geoffrey Woo, is a venture capital firm breaking from traditional norms. With a focus on frontier technologies like AI, machine learning, blockchain, and digital health, the fund is built around the philosophy that capital alone isn’t enough—attention and cultural impact are equally critical. Anti Fund's investments include standout startups like Alchemy, Manifold, Osmind, and Moonpay. Based in Miami, the firm targets early-stage ventures, investing between $100,000 and $1 million per deal. Anti Fund primarily backs bold founders who can command attention and challenge industry paradigms. The team uses AngelList’s Rolling Fund model, allowing LPs to subscribe quarterly. Backed by prominent investors such as Marc Andreessen and Chris Dixon, the fund has gained quick traction. The fund’s strategy is centered on reshaping the cultural landscape, blending capital with the founders' ability to create significant market demand. This unique approach reflects both Paul’s background in entertainment and Woo’s expertise in tech entrepreneurship.

Antler is a globally renowned early-stage venture capital firm known as the "day zero investor," backing founders from the inception of their startups. With over 850 investments in 20+ countries, Antler has notable portfolio companies like Airalo, a global eSIM provider, and has recently raised a $60 million MENAP fund to further support startups in the Middle East, North Africa, and Pakistan region. Antler focuses on sectors including technology, fintech, and digital innovation, providing personalized coaching, co-founder matching, and follow-on funding. Key team members include Dr. Jonathan Doerr and Romain Assunção, leading regional activities from Riyadh and Duba

Anzu Partners is a venture capital firm founded in 2014, focusing on breakthrough industrial and life sciences technologies. Headquartered in Washington, D.C., with additional offices in Boston, San Diego, and Tampa, the firm manages over $1 billion in strategic assets across various funds and investment strategies. Anzu Partners has a robust portfolio of around 40 companies, including notable investments in e-Zinc, Framework, EnCharge, AM Batteries, and Arduino. The firm has also achieved significant exits, such as NUBURU and Ai-Media, highlighting its capability to support companies from early stages through to successful public offerings or acquisitions. Anzu specializes in three primary investment solutions: venture capital investments, debt and revenue-based investments, and Special Purpose Acquisition Companies (SPACs). The firm provides not just capital but also deep expertise in business development, market positioning, global connectivity, and operations, helping to drive the commercial success of its portfolio companies. The leadership team at Anzu Partners includes experienced professionals like Managing Partners David Michael, David Seldin, and Whitney Haring-Smith, who bring decades of combined experience in global investments and consultancy. This expertise is further supported by a dedicated team of technical and operational professionals.

Aonia Ventures is a Paris-based micro-VC firm founded in 2020 with roots in Switzerland, investing in 20 to 30 technology startups per year worldwide at seed and Series A stages. The firm deploys €100K to €250K per deal across healthtech, fintech, greentech, foodtech, wellness, and lifestyle — sectors where Aonia sees urgent problems and scalable solutions converging. A team of three partners runs the fund, maintaining a high-volume, hands-on investment cadence across Europe and the United States. With 55 portfolio companies and counting, Aonia has accumulated a track record that includes one unicorn — Alan, the French health insurance platform — and one public market exit via Field Trip Health and Wellness. These outcomes anchor the portfolio's credibility against a backdrop of broad, consistent early-stage deployment across multiple sectors and geographies. Aonia's model is deliberately high-frequency: by writing smaller checks across a large number of bets each year, the firm maximizes exposure to breakout outcomes while building a portfolio network with compounding cross-sector value. The fund's particular strength in health and wellness, combined with greentech and fintech coverage, reflects founders' growing interest in businesses that address large systemic challenges — a thesis Aonia has pursued since its founding and continues to refine with each cohort of investments.

APA Venture Partners is a San Francisco-based pre-seed and seed-stage venture capital firm founded in 2020, focused on founders who are automating legacy industries. The firm targets healthcare, B2B SaaS, and consumer technology — sectors where outdated processes create substantial displacement opportunity for technology-led challengers. APA was founded by individuals with significant institutional VC and company-building experience, combining that background with high-touch operational support and curated access to Fortune 500 companies. The firm leads rounds and typically writes checks of $100K to $1 million, with 16 investments to date across its target sectors. Portfolio companies include DataPlor, a location intelligence data company, alongside other early-stage businesses in logistics and consumer mobility. APA invests exclusively in the United States, maintaining a national scope while operating from its San Francisco base. APA Venture Partners calls its target founders 'rule-breakers' — operators who have identified inefficiencies in established industries and possess the domain expertise to replace incumbent processes with better technology. The firm's value proposition extends well beyond capital: the team provides hands-on operational guidance and broker introductions to major corporate partners, giving portfolio companies a meaningful commercial runway advantage in the earliest, most fragile stage of company building.

Apax Partners is a leading global private equity advisory firm with a focus on inspiring growth and transforming businesses. Founded nearly 50 years ago, Apax has raised and advised over 30 funds, managing more than $77 billion in aggregate capital. The firm primarily invests in four sectors: Tech, Services, Healthcare, and Internet/Consumer. Apax operates several strategic funds, including Apax Global Buyout, which focuses on transformative growth in key sectors, and Apax Digital Growth, aimed at accelerating tech companies. Additionally, Apax Global Impact targets companies that deliver tangible societal and environmental benefits, while Apax Mid-Market Israel leverages local expertise to support growth in Israeli businesses. The firm also has Apax Credit and Apax Listed Private Equity strategies to provide a flexible investment approach across the capital structure​. Notable investments include Auto Trader Group, GlobalLogic, and Cole Haan, among others. Apax leverages its deep sector expertise and global network to drive operational excellence and digital transformation within its portfolio companies. The firm’s extensive experience and strategic focus have made it a prominent player in private equity globally, with offices in major financial hubs including London, New York, Hong Kong, and Tel Aviv​.

Aperture Venture Capital (Aperture VC) is a venture capital firm founded in 2021, based in Radnor, Pennsylvania. The firm focuses on investing in early-stage companies, particularly those led by diverse founders who are building the future of fintech and enterprise software. Aperture VC's mission is to redefine the venture capital landscape by supporting the "Multicultural Mainstream," which includes Black, Latinx, and female entrepreneurs. Aperture VC’s unique approach involves its Diversity Investing API℠, a platform designed to connect corporate partners with diverse talent and market innovations. This platform also provides portfolio companies with critical operating resources to help them scale. The firm believes that by investing in diverse founders, they can unlock untapped potential and drive significant impact in the venture capital ecosystem. Aperture VC has quickly gained recognition in the industry, attracting investments from major corporations like PayPal, which have recognized the value of supporting diverse founders. The firm is committed to fostering an inclusive ecosystem where diverse entrepreneurs can thrive and achieve successful exits.

APEX Ventures is a venture capital firm based in Vienna, Austria, specializing in deep tech and medical technology startups. Founded in 2016, APEX Ventures invests in early-stage companies across Europe, with a focus on innovations in AI, quantum computing, automation, robotics, computer vision, space technology, and medical technology. The firm emphasizes backing startups with unique, defensible technologies that have the potential to disrupt and transform their respective industries​. In 2023, APEX Ventures partnered with Amadeus Capital Partners to launch the Amadeus APEX Technology Fund, which aims to raise €80 million to support deep tech startups primarily in the DACH region (Germany, Austria, and Switzerland). This fund focuses on seed and Series A investments, typically ranging from €1 million to €1.5 million. The partnership combines APEX’s local expertise and network with Amadeus’ extensive global experience in venture capital. APEX Ventures has a diverse portfolio, including companies like contextflow, ImageBiopsy Lab, and Mobius Labs. The firm is known for providing not just capital but also strategic support, leveraging their deep tech expertise and strong networks to help startups scale and succeed​.

Apollo Global Management, a leading global alternative investment manager, has a diverse and extensive portfolio across various sectors. As of 2024, Apollo manages approximately $548 billion in assets, with substantial investments in private equity, credit, and real estate. In the private equity space, Apollo's portfolio includes companies like ADT Inc., a major provider of security and automation solutions; CareerBuilder, an online employment service; and The Fresh Market, a specialty grocery retailer. They also have significant holdings in the healthcare sector with companies like LifePoint Health and R1 RCM Inc. Apollo is known for its strategic acquisitions across multiple industries. Notable recent acquisitions include U.S. Silica, a producer and supplier of silica sand, and Modern Aviation, a premium aviation services provider. Additionally, Apollo has made significant investments in the travel and hospitality sector, exemplified by its acquisition of Great Wolf Resorts and Diamond Resorts International. The firm's investment strategy focuses on creating value through buyouts, corporate carve-outs, and distressed asset investments. This approach has enabled Apollo to build a robust portfolio that spans various geographies, primarily the United States and the United Kingdom, with a strong presence in the energy and financial services sectors.

Apollo Projects, spearheaded by the Altman brothers—Sam, Jack, and Max—is a venture capital firm that specializes in funding transformative, early-stage companies. With a focus on "moonshots," Apollo targets startups with the potential to disrupt industries and create significant societal impact. Their portfolio boasts notable investments like KoBold Metals, which uses artificial intelligence for mineral exploration, and Glydways, a revolutionary transportation company. Apollo Projects is particularly active in sectors such as AI, renewable energy, and advanced biotechnology, where innovation can drive profound change. The firm typically leads funding rounds, writing substantial checks to support the ambitious goals of its portfolio companies. Apollo's investment strategy is centered around identifying and nurturing startups that are not only innovative but also have a clear vision for large-scale impact. They are especially interested in companies that challenge the status quo and push the boundaries of technology and industry norms. With a seasoned team led by the Altman brothers—each bringing a wealth of experience from their diverse backgrounds—Apollo Projects offers more than just capital. They provide strategic guidance and a deep network of industry connections, making them an invaluable partner for startups aiming to scale quickly and effectively. Entrepreneurs with bold, disruptive ideas often find Apollo Projects to be an ideal ally in their journey to bring groundbreaking technologies to market. This combination of financial backing, expertise, and a shared vision for the future positions Apollo Projects as a pivotal force in the venture capital landscape.

Apollo Health Ventures is a transatlantic venture capital firm founded in 2016 and headquartered in Berlin, Germany. Co-founded and led by Managing Director Nils Regge, the firm's singular mission is to fund and co-build companies that target the root causes of aging and age-related diseases. Apollo focuses on breakthrough science in Alzheimer's disease, heart disease, cancer, sarcopenia, and frailty — with the ultimate goal of extending healthy human lifespan. The firm takes an active company-building role, frequently co-founding portfolio companies alongside scientists and entrepreneurs. Apollo leads rounds and has made approximately 13 investments across Seed and Series A stages, with seed rounds averaging $9.7 million and Series A rounds averaging $34 million. Notable portfolio companies include Auron Therapeutics, HAYA Therapeutics, Cleara Biotech, Cognito Therapeutics, and Aeovian Pharmaceuticals. The portfolio spans the United States and Europe, reflecting the firm's transatlantic orientation and its Bio Fund I structure. Apollo Health Ventures differentiates itself through its company-building model: the team does not passively invest in existing longevity companies but actively participates in their creation, recruiting scientists, shaping research strategy, and guiding early clinical positioning. This founder-in-residence approach concentrates portfolio expertise in a narrow therapeutic category and allows Apollo to shape the science from the earliest stages — well before most investors enter the conversation.

Applied Ventures is the venture capital arm of Applied Materials, based in Santa Clara, California. Since its establishment in 2006, the firm has focused on early-stage investments, primarily within deep technology sectors such as semiconductors, energy, advanced materials, and life sciences. Applied Ventures has a global reach, with investments spanning across North America, Europe, Asia-Pacific, and the Middle East. The firm is known for its flexibility, investing up to $100 million annually and actively participating in funding rounds ranging from $10 to $50 million. Its strategy emphasizes supporting startups with disruptive technologies by connecting them to Applied Materials' global ecosystem, which includes industry partners, supply chain resources, and technical expertise. Key portfolio companies include Ayar Labs (optical I/O technology), Rockley Photonics, and TXOne Networks, reflecting its focus on innovations that align with Applied Materials' core strengths in materials engineering and semiconductor technology​. The investment team is led by Anand Kamannavar, who serves as Global Head, alongside key figures such as Brad McManus, John Wei, and Rajesh Ramanujam, all based in Santa Clara. Applied Ventures is stage-agnostic, supporting both early and growth-stage startups as they scale globally, especially those involved in deep tech advancements.

Aquilo Capital Management is a biotech-focused investment firm based in San Francisco, established in 2010. The firm specializes in funding drug development companies that utilize cutting-edge science to address urgent medical needs. Aquilo’s approach is rooted in deep sector expertise and a disciplined, value-oriented investment strategy. They focus on identifying biotech companies with the potential to create transformative therapeutics that can significantly impact healthcare and society. The firm’s investment strategy is heavily concentrated in life sciences, targeting innovative drug discovery and development projects. They aim to balance risk with high potential returns, favoring companies that are on the cusp of delivering paradigm-shifting treatments. Aquilo employs both a long-only and hedged investment strategy, giving them flexibility and resilience in volatile markets. Notable investments include pioneering biotech firms like Arrowhead Pharmaceuticals and Regenxbio. Aquilo Capital is led by founder and CIO Marc Schneidman, who brings over 20 years of experience in the biotech investment space. The firm takes a global perspective, with a keen interest in leveraging opportunities in both the U.S. and Europe. They are known for supporting early-stage ventures and maintaining strong relationships with the scientific and biotech communities. Aquilo’s mission is to bridge the gap between groundbreaking science and successful commercial application, delivering both societal benefits and strong returns for investors.

Aramco Ventures is the corporate venture capital arm of Saudi Aramco, one of the world’s largest integrated energy and chemicals companies. Established in 2012, the fund has grown significantly, recently receiving an additional $4 billion, bringing its total capital to $7.5 billion. This expansion supports Aramco's long-term strategy of investing in technologies critical to energy transition and sustainability. Aramco Ventures operates through several specialized funds, including its Prosperity7 and Sustainability Fund, focusing on sectors such as carbon management, hydrogen, renewables, AI, and advanced materials. The firm has made over 140 investments globally, backing companies like Promethean Particles and Seeq that align with its strategic goals of advancing low-carbon and innovative technologies. The fund is headquartered in Dhahran, Saudi Arabia, and led by CEO Mahdi Aladel. It actively seeks out companies that can contribute to the global energy transition, emphasizing technologies that offer scalable solutions to the challenges facing the energy sector today​.

Aravaipa Ventures is a Boulder, Colorado-based venture capital firm founded in 2008 by Robert Fenwick-Smith, focusing exclusively on what the firm calls Impact Technologies — disruptive technology companies with measurable global environmental benefit. Aravaipa is notable as the only fund in the United States with a singular mandate in this category, targeting companies across transportation efficiency, building efficiency, water treatment, and smart agriculture. Fund II (AGEF2) targets $30 million and seeks 3-year returns of 5x to 10x. The firm leads rounds and deploys $250K to $1 million initially, targeting companies that already generate revenue or expect to do so rapidly and can reach profitability on less than $10 million in additional capital. With 11 investments to date, the portfolio includes Bolder Industries, Sionic Energy, Clear Comfort Water, and Lightning eMotors, which completed a public market exit. Silver Bullet was acquired. The firm co-invests alongside a Colorado-anchored syndicate that includes Factor[E], King Hill Capital, and Bohemian Companies. Aravaipa's capital-efficiency thesis is deliberate: by targeting companies that can become profitable $20 to $200 million revenue businesses without mega-rounds, the firm minimizes both dilution risk and funding dependency for founders. Robert Fenwick-Smith's environmental impact mandate extends beyond portfolio selection into active operational guidance, helping portfolio companies navigate both the technical and regulatory dimensions of bringing environmental technologies to market.

Aravis is a private equity firm based in Zurich, Switzerland, founded in 2001 by Jean-Philippe Tripet. The firm focuses on high-tech growth investments, primarily in the biotech, creative and digital, and industrial high-tech sectors. Aravis has sponsored multiple fund vintages and has deployed over USD 400 million across four funds. Aravis Growth I LP, their latest initiative, targets investments in established, innovative Swiss and European companies with significant growth potential. This fund aims to fill the gap in growth capital in the region by offering strategic advice, access to networks, and capital to accelerate companies through their growth phases​. The team at Aravis is composed of experienced professionals from various backgrounds, including finance, industry, and technology, providing a wealth of knowledge and expertise to support their portfolio companies. Their investment approach also integrates ESG criteria, aligning with several UN Sustainable Development Goals (SDGs).

Arbor Ventures is a Singapore-based fintech venture capital firm founded in 2013 by Melissa Guzy and Wei Hopeman. With $519 million in assets under management across eight funds — including Fund I at $125 million and Fund II at $235 million — Arbor focuses on companies leveraging advanced technology to transform financial services. The firm's fintech mandate is broadly defined, encompassing regtech, insurtech, cybersecurity, AI, and blockchain across North America, Europe, and Asia. The firm leads rounds and has made 85 investments, backed by a team of 15 including seven partners. Arbor's track record is among the strongest in Asian venture: six portfolio unicorns including Tabby and Akulaku, two IPOs — Grab on NASDAQ at a $40 billion market cap in 2021 and Lufax on the NYSE — and 11 acquisitions including EverC, acquired by G2 Risk Solutions. Additional portfolio companies include Fundbox, Paidy, and AppliedAI. The firm invests primarily at Seed and Series A, deploying $3 million to $20 million per company, with the largest concentration of investments in the United States followed by Israel. Arbor Ventures built its edge through cross-border network density: connecting entrepreneurs, corporations, and capital across Asia, the US, and Europe before most fintech-focused funds saw the category as global. Guzy and Hopeman's combined expertise in financial services technology and international market-building gives portfolio companies an accelerated path to geographic expansion that few early-stage investors in fintech can match.

Arboretum Ventures, headquartered in Ann Arbor, Michigan, is a prominent venture capital firm specializing in the healthcare sector. Founded in 2002 by Jan Garfinkle and Tim Petersen, the firm manages $1 billion across six funds. Arboretum Ventures focuses on capital-efficient investment opportunities in medical devices, life science tools, diagnostics, tech-enabled care delivery, and pharma adjacencies​. The firm has a strong commitment to investing in under-ventured geographies, particularly in the Midwest. Their portfolio includes a variety of innovative companies such as NeuMoDx, which was acquired by QIAGEN, and Fifth Eye, known for its early warning system for patient care​. Arboretum's investment strategy emphasizes supporting startups that aim to reduce healthcare costs while improving patient outcomes. They are active partners, providing strategic guidance and leveraging their extensive network to help portfolio companies succeed. The team includes managing partners Jan Garfinkle, Dr. Tom Shehab, Dan Kidle, and other key members like Paul McCreadie and Marcy Marshall. Overall, Arboretum Ventures stands out for its proactive involvement with entrepreneurs and its focus on transformative healthcare solutions that address significant industry challenges​,

Arborview Capital is a private equity firm headquartered in Chevy Chase, Maryland, founded in 2008. The firm focuses on investing in impact-driven, high-growth companies that contribute to sustainability and resource efficiency. With a deep commitment to environmental stewardship, Arborview seeks to back companies that drive positive change across industries like energy efficiency, sustainable agriculture, water conservation, and waste reduction. Their portfolio includes standout companies like Vital Farms, TemperPack, Rachio, and Copper Cow Coffee, all recognized for pushing the boundaries of sustainability and innovation. Arborview Capital typically invests between $5 million and $15 million, engaging with companies that generate at least $5 million in revenue and have a clear path to profitability. Their investment strategy is built around creating concentrated portfolios, allowing them to take a hands-on approach and form deep, strategic partnerships with management teams. They are open to leading rounds or co-investing, and often hold board positions, ensuring active involvement in scaling their companies. Geographically, Arborview primarily invests in U.S.-based companies, though they also explore opportunities in Canada and Mexico. As a B Corp certified firm, they align their financial goals with their commitment to creating lasting environmental impact, prioritizing patient capital over quick exits. Led by co-founders Joseph Lipscomb and Karl Khoury, alongside a seasoned team, Arborview prides itself on being a values-driven firm. Their approach combines deep industry expertise with a genuine passion for sustainability, making them trusted partners for entrepreneurs looking to scale impactful businesses.

Arch Venture Partners is a powerhouse in venture capital, specializing in early-stage investments in life sciences and technology. With a notable portfolio that includes industry leaders like Grail, Illumina, and Denali Therapeutics, Arch focuses on groundbreaking innovations that transform healthcare and biotech. They have a strong geographic footprint in the United States, with significant investments also in China and the UK. Their investment strategy centers on nurturing disruptive technologies with high-impact potential. Arch Venture Partners typically leads investment rounds, deploying substantial capital to accelerate growth, evidenced by their recent $2.975 billion Fund XII. The firm prioritizes deep scientific expertise and collaborates closely with founders to guide long-term strategic development. Average check sizes vary, but their robust funding capabilities mean they often make sizable commitments. Founded in 1986, Arch is driven by a team of seasoned professionals, including co-founder Robert Nelsen, who has been instrumental in the success of numerous billion-dollar companies. The firm values direct and collaborative approaches from startups, emphasizing the importance of innovative ideas backed by solid research. Overall, Arch Venture Partners stands out for its dedication to pioneering science and technology, its active role in funding and strategy, and its impressive track record of high-profile successes.

Archetype is an early-stage venture capital firm based in New York City, specializing in the cryptocurrency and blockchain sectors. Established to accelerate the decentralized future, Archetype focuses on backing the next generation of crypto founders who are dedicated to creating entirely new markets and disrupting the status quo. The firm brings extensive experience in investing, engineering, operations, policy, and community-building to support innovative builders from the ground up. Archetype's notable investments include companies like Movement Labs, which develops blockchain infrastructure; Stack, a platform for secure digital asset storage; and Lagrange, which focuses on decentralized finance (DeFi) solutions. Other significant investments are in companies such as Ritual, a Web3 platform for content creators, and Socket, a developer of interoperability solutions for blockchain networks. The firm is led by a crypto-native team with diverse backgrounds, including investing, technology, and community engagement, ensuring that their portfolio companies receive comprehensive support. Archetype’s mission is to help founders go from concept to market, leveraging their unique expertise and extensive network to foster success in the decentralized technology landscape.

Archetype is an early-stage venture capital firm that focuses on accelerating the decentralized future, primarily backing startups in the Web3 and cryptocurrency space. Founded in 2021 and based in New York, Archetype is led by founder Ash Egan and a team of experienced professionals from the crypto, investing, and engineering worlds. The firm invests in seed-stage companies, with check sizes typically ranging from $1M to $3M. They also lead many of their funding rounds. Archetype is known for backing founders who are disrupting traditional industries by creating entirely new markets within the decentralized economy. The firm's portfolio includes standout names like Alchemy, Socket, and Mona, all of which focus on cutting-edge technologies in crypto infrastructure, blockchain development, and decentralized applications. Archetype’s investment philosophy is centered on supporting founders with deep technical expertise and a vision for decentralization. They are highly active in the U.S., with a particular focus on startups that bring innovation to financial services, infrastructure, and software development. The firm also provides strategic guidance, leveraging its team’s extensive network within the crypto ecosystem to help startups grow from concept to market-ready products. By combining their expertise in both technology and operations, Archetype positions itself as a critical partner for crypto founders looking to build and scale innovative projects in the decentralized world.

Archimed Group, founded in 2014 and headquartered in Lyon, France, is a leading private equity firm specializing in the healthcare sector. The firm manages around €8 billion in assets and is focused on investing in small to midsize companies across seven key healthcare sectors, including Biopharma, MedTech, and Healthcare IT. Archimed’s strategy involves acquiring majority stakes in companies and working closely with them to accelerate growth, drive innovation, and expand internationally. Archimed has a strong track record, with its funds consistently ranking in the top decile for performance. The firm’s latest fund, MED Platform II, closed at €3.5 billion in 2023, making it the largest healthcare-only private equity fund raised by a European-based firm. This fund is primarily focused on mid-cap companies in Europe and North America, aiming to support healthcare leaders in scaling their operations through strategic acquisitions and capacity expansions. Archimed’s commitment to impact investing is evident through its alignment with sustainable development goals and its EURÊKA Foundation, which supports healthcare-related charitable initiatives. The firm’s unique blend of financial, medical, and operational expertise positions it as a key player in the global healthcare investment landscape.

Architect Partners Ventures is the direct investment arm of Architect Partners (AP), the leading crypto mergers and acquisitions and strategic financing advisory firm, founded in 2009 by Eric Risley and co-led with Steve Payne. The broader firm has advised on major transactions including Securitize's acquisition of Velocity Capital Markets, Polygon Labs' intended acquisitions of Coinme and Sequence, and Champ Titles' $18 million Series C. The ventures unit extends this advisory platform into direct early-stage investing in the crypto and fintech ecosystem. The fund deploys $10K to $100K — with a sweet spot of $25K — at pre-seed and seed stages globally across Web3 and blockchain, digital assets, fintech, data analytics, advertising technology, and marketplaces. With 14 investments and a distributed team across the San Francisco Bay Area, New York, and Southern California, Architect Partners Ventures occupies a niche as a seed investor with direct access to crypto M&A flow and strategic intelligence. The firm publishes widely-followed research including crypto M&A alerts and sector topology reports. The ventures arm's primary advantage is informational: operating at the intersection of M&A advisory and direct investing gives the team unusual visibility into acquirer appetites, strategic gaps, and valuation benchmarks across the crypto ecosystem. Founders who take capital from Architect Partners gain not just a check but a firm that understands how their company might ultimately be acquired, licensed, or merged — and is actively working those relationships on their behalf.

Arcus Ventures is a New York-based venture capital firm founded in 2007 by Steven L. Soignet and James B. Dougherty, dedicated exclusively to oncology-focused life sciences companies. The team brings deep experience across clinical and academic medicine, drug development, hospital management, healthcare consulting, and private equity — a multi-disciplinary foundation that informs both investment selection and portfolio support. The firm closed a cancer-focused fund at $45 million in August 2014. Arcus leads rounds and targets three opportunity types: innovative biopharmaceuticals or drug delivery platforms in development, medical device companies approaching pre-marketing approval, and commercial-stage service businesses with positive revenue. Check sizes of $1 million to $5 million are deployed at Series A and Series B stages across North America and Europe. Notable portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, T2 Biosystems, and Vascular Pathways, collectively spanning drug discovery, diagnostics, biopharmaceuticals, and medical devices. Arcus Ventures' singular sector focus is its defining characteristic: by investing only in oncology, the firm develops a depth of scientific and commercial judgment that generalist healthcare funds cannot replicate. Soignet and Dougherty's combined clinical and entrepreneurial backgrounds allow them to evaluate not only the science but the regulatory and commercial pathway — providing portfolio companies with guidance that is specific, experienced, and directly applicable to the challenges of bringing cancer therapies to market.

Arcview Ventures is the corporate venture capital arm of The Arcview Group, the largest and first vertically integrated firm serving the cannabis industry. Launched in early 2020 and based in New York, Arcview Ventures is a member-managed fund that pools capital and strategic relationships among cannabis industry insiders to make collective investment decisions. The Arcview Group was founded in 2010 in San Francisco and has been recognized by Forbes as one of the top five financial firms in the cannabis sector. The broader Arcview Investor Network has collectively invested more than $270 million in over 200 cannabis companies. Arcview Ventures co-led by CEO Jeffrey Finkle and CIO Jeanne Sullivan focuses on seed and early-stage deals, deploying $75K to $250K per investment across cannabis and hemp subsectors including agricultural technology, pharmaceuticals, biotechnology, software, and ancillary products. The fund has made 15 investments, including Hoodie Analytics, Green Check Verified, and Katalys, with activity in the United States, Israel, and Canada. The fund's member-managed structure is both its point of differentiation and its source of deal flow advantage: members are active cannabis industry operators and investors who evaluate opportunities collectively, combining domain expertise with pooled capital. For cannabis entrepreneurs, Arcview Ventures provides not only funding but access to the deepest professional network in the sector — one built on over a decade of advocacy, deal sourcing, and industry relationship building.

Ardent Venture Partners is a Washington, D.C.-based venture capital firm founded in 2020 by Philip Bronner and Philip Herget. The firm focuses on early-stage investments, particularly in AI-native applications, vertical SaaS, and B2B fintech. Ardent has a reputation for backing disruptive startups that modernize traditional enterprise software and enable new financial technologies. Ardent's portfolio includes notable companies like Verituity, Method Financial, and Pickleheads. The firm is especially bullish on embedded finance, where software companies integrate financial services directly into their platforms, and sees tremendous opportunities in modernizing B2B payments and banking technologies. Ardent typically leads early-stage rounds and emphasizes hands-on operational support, drawing on the extensive entrepreneurial and investment experience of its partners​. The firm's geographic focus spans key U.S. tech hubs like Washington, D.C., and New York, with a commitment to supporting the digital transformation of industries heavily reliant on outdated systems.

Aleph VC, founded in 2013 and based in Tel Aviv, specializes in early-stage investments, primarily partnering with Israeli entrepreneurs. With $850 million under management, Aleph focuses on building meaningful companies and impactful global brands across various sectors, including fintech, digital health, cybersecurity, AI, and machine learning. Notable investments by Aleph include Lemonade, a full-stack global insurance company, and Melio, which provides digital payment tools for small businesses. Other prominent portfolio companies include Nexar, a dashcam and edge-AI platform for better driving, and Freightos, a digital freight marketplace. The firm has also seen significant exits, such as the acquisition of Raftt and the public offering of Freightos​. Aleph typically invests between $2 million and $12 million in seed and pre-seed stages, focusing on innovative companies poised for global expansion. The team, led by co-founders Michael Eisenberg and Eden Shochat, leverages their extensive network and expertise to provide strategic guidance and access to global markets, aiming to create long-term value for their portfolio companies.

Arena Ventures is a seed-stage venture capital firm based in Los Angeles and San Francisco, founded in 2015 by Jeff Lo and Paige Craig. The firm backs technology startups led by entrepreneurs who are uniquely positioned to transform their industry — with particular focus on what the team calls atypical founding teams: people whose unconventional backgrounds give them asymmetric insight into the problems they are solving. Arena is also notable as the first venture firm built from the ground up to collaborate with equity crowdfunding, helping AngelList backers become more effective investors. With 45 investments and eight portfolio exits — most recently Betterview in December 2023 — Arena Ventures has backed Clover Health, which went public via SPAC, and Andela, the talent marketplace that became a unicorn. Atrium LTS represents the firm's legal technology exposure. The fund writes checks of $100K to $1 million at Seed and Series A stages and invests exclusively in North America across software, fintech, healthtech, food and beverage, education, and real estate. Arena Ventures takes a disciplined approach to founder selection: the team invests heavily in understanding each founder's personal background and psychological makeup before committing capital. This founder-first philosophy translates into a small annual deal count — two to six investments per year — and sustained support well past the initial check, with the team described as willing to fight hard alongside founders through difficult stretches.

Argon Ventures, based in Cambridge, Massachusetts, is a pre-seed venture fund focusing on Intelligent Industry Solutions. Founded by Robert Mason and Andrew Feinberg in 2020, Argon Ventures targets early-stage investments in Big Data & Analytics, SaaS, and Software sectors. The firm leverages its deep operational expertise to support founders in building impactful global businesses. Notable investments include companies like EnFi, Cyvl.ai, and PeakMetrics, reflecting Argon's commitment to high-tech, data-driven solutions. Argon Ventures typically leads rounds with an average investment size of around $2M, showing a preference for hands-on engagement from the earliest stages. The firm has built a strong co-investor network, collaborating with prominent investors such as Techstars and Glasswing Ventures. Argon Ventures is characterized by its proactive support in areas like team building, product strategy, and market entry. The team, including seasoned professionals like Bob Mason, brings a combination of technical insight and business acumen, helping startups navigate their growth journeys effectively. With a robust portfolio and a strategic focus on innovative tech solutions, Argon Ventures positions itself as a key player in the venture capital landscape, fostering the next generation of transformative companies.

Aria Ventures is a Birmingham, Michigan-based venture builder and early-stage investor founded in 2002 by Jeff Sloan. Rather than operating as a conventional VC fund, Aria provides critical development services to growing businesses in a performance-driven model: in exchange for providing resources, operational support, and strategic packaging, the firm takes equity as a long-term partner. This venture-builder orientation distinguishes Aria from funds that deploy capital without hands-on involvement. The team of three partners supports a portfolio of approximately 10 investments spanning technology, consumer, and enterprise software sectors. Aria writes checks of $100K to $1 million at pre-seed and seed stages and leads rounds, working across software, AI, hardware and robotics, and consumer technology in the United States. More recently, the firm launched a LE 50 million fund (approximately $1 million USD, with plans to grow to LE 200 million by 2029) targeting early-stage deep-tech companies in Egypt's startup ecosystem — specifically artificial intelligence, robotics, biotechnology, nanotechnology, and the Internet of Things. Aria Ventures' expansion into Egypt reflects a conviction that frontier technology talent exists well outside the established venture hubs and that hands-on operational support — not just capital — is the scarce resource that enables early-stage deep-tech companies to commercialize. The firm's dual presence in Michigan and the MENA region gives it an unusual geographic footprint for a fund of its size.

Aristos Ventures is a Dallas, Texas-based micro venture capital firm founded in 2011 by Managing Partner Felipe Mendoza, with $14 million in assets under management. The firm is explicitly modeled after the classic venture capital approach of the 1980-1993 era — when average investment sizes were $2 million and fund sizes were $35 million — arguing that this capital-efficient, high-conviction model produced the best returns and the most enduring technology companies. Aristos targets highly capital-efficient tech companies across Texas, with a specific focus on Austin, Dallas, Houston, and San Antonio. The firm leads rounds and deploys $200K to $1 million per investment at seed and Series A stages, targeting exits in the $5 to $20 million range. With 17 investments to date, Aristos has backed CloudCoreo (acquired by VMware), Netsocket (acquired by iPhotonix), Theatro, Nesh, Traxo, JamKazam, Nimbix, and InvoiceCare, among others. The team operates with an extended network of Venture Partners comprising seasoned entrepreneurs and investors embedded in the Texas tech ecosystem. Aristos Ventures' thesis cuts against the grain of the large-fund era: by keeping fund size modest and targeting smaller exits, the firm argues it can generate strong returns that larger funds cannot pursue. Mendoza's focus on the Texas market reflects both geographic conviction and a belief that the state's growing technology density creates sustainable deal flow for a disciplined, small-check investor with deep regional relationships.

Arix Bioscience is a global venture capital firm based in London, specializing in biotechnology investments. Founded in 2016, Arix focuses on backing early-stage companies that are developing breakthrough treatments and technologies in the life sciences sector. Their investment strategy targets ventures from late pre-clinical to clinical stages, emphasizing a diversified portfolio to mitigate risks inherent in biotech investments​. The firm has built a robust portfolio that includes companies like Autolus, a developer of CAR-T cell therapies for cancer, and Disc Medicine, which focuses on treatments for hematologic diseases. Arix has also been involved in significant financing rounds, such as the $50 million Series B for Evommune and Ensoma, highlighting their role in advancing innovative biotech startups. Arix operates a permanent capital model, allowing it to support its portfolio companies through market fluctuations without being bound by strict exit timelines. This approach enables them to provide sustained support to their investments, which is critical in the high-risk, high-reward biotech sector.

Arka Venture Labs is a cross-border pre-seed and seed fund enabling B2B entrepreneurs building from India to scale globally. The firm provides startups with capital, mentorship, and deep access to both the Silicon Valley and Indian startup ecosystems, operating out of Blume Ventures' offices in India and BGV's offices in the US. Arka Fund II, anchored by BGV, focuses specifically on pre-seed and seed-stage US-India enterprise AI companies headquartered in the United States with engineering and operations in India. The fund writes checks up to $500K, typically in the form of preferred equity, SAFE, or convertible notes, and leads rounds as the first institutional investor. With 40 investments across SaaS, AI, B2B software, and data analytics, portfolio companies have raised over $100 million in follow-on financing, with six crossing $1 million in ARR and nine exits. Notable portfolio companies include Lyzr, Bruviti, and Xcaliber. Four new investments were made in the most recent twelve-month period. Arka's core insight is structural: the best enterprise B2B companies of the next decade will increasingly be built with Silicon Valley distribution and Indian engineering, but most venture funds are optimized for one geography and not both. By combining Blume's knowledge of India's entrepreneurial ecosystem with BGV's operational track record in B2B cross-border investments, Arka offers founders a genuine bridge — not just a check — across the US-India corridor.

Arkin Bio Ventures is a Tel Aviv-based life sciences venture capital firm founded in 2016 as part of Arkin Capital, a diversified global investment manager with over $2 billion in assets under management across twelve funds. Arkin Bio operates as a joint venture between Phoenix Group (49%) and Arkin Holdings (51%), and has raised three funds: Fund I in 2016, Fund II at $140 million in 2020, and Fund III at $100 million closed in January 2026 — bringing total life sciences AUM above $600 million. Managing Partner Dr. Pini Orbach and Partner Alon Lazarus lead a team of ten, including four partners. The firm leads rounds and invests $3 million to $20 million per company at early and mid-stage in biotech companies developing therapies in immunotherapy, cancer, metabolism, microbiome, autoimmune diseases, and drug delivery. With 27-plus investments and more than 20 successful exits through IPOs and acquisitions, Arkin Bio has backed UroGen Pharma, Keros Therapeutics, Bluejay Therapeutics, cCAM Biotherapeutics, Hi-Bio, and ImmPACT Bio, among others. Arkin Bio's partnership with Phoenix Group provides co-investment capacity that extends individual deal capability and supports portfolio companies through multiple rounds. The team works closely with founders on biological strategy, translational planning, and clinical positioning — going well beyond check-writing to serve as active scientific and commercial advisors during the most capital-intensive stages of drug development.

Arkitekt Ventures is a New York-based venture capital firm focused on advancing human health through early-stage investments. Their portfolio emphasizes innovative healthcare solutions, including digital health platforms, biotech, and frontier technologies like neurotech, AI, and bioengineering. Notable recent investments include Sollis Health, Nanite, and Mural Health, with check sizes ranging from $3M to $15M. Arkitekt primarily invests in the U.S. but has also backed companies in the UK, maintaining a sector focus in healthtech, medical devices, and life sciences. Their strategy centers on pre-seed to Series A stages, preferring startups with groundbreaking approaches to healthcare delivery and precision medicine. They rarely lead rounds but frequently co-invest with prominent partners like Bessemer Venture Partners and Torch Capital. Led by managing director Enke Bashllari and partner Pavan Choksi, Arkitekt Ventures values long-term partnerships and tends to back visionary founders who are leveraging cutting-edge science. Their team prefers a data-driven, relationship-building approach, and startups seeking funding should ideally present transformative technologies with strong early traction.

Arkley Brinc VC is a venture capital firm based in Warsaw, Poland, that focuses on early-stage investments in hardware-enabled startups, particularly in IoT, MedTech, and smart manufacturing sectors. The firm was established as a joint initiative between Arkley, a European pioneer in hardware investments, and Brinc, a global accelerator known for its deep connections in China’s manufacturing hubs. This partnership allows Arkley Brinc to offer startups not only capital but also a wealth of resources for product development, manufacturing, and global distribution. With a fund size of $15 million, Arkley Brinc invests up to $1 million per company, supporting them from the prototype stage through to IPO. The firm’s investments are concentrated in Poland and across Europe, leveraging its strategic networks to help startups scale effectively. Arkley Brinc has a strong track record, with over 50 projects supported and several successful exits and IPOs. The firm’s team consists of serial entrepreneurs and finance professionals with extensive experience in launching and scaling technology businesses. The Arkley Launchpad program is another key initiative, offering a highly individualized acceleration program designed to raise successful funding rounds and drive operational success. This program is tailored to the specific needs of each startup, providing access to a network of partners in prototyping, manufacturing, sales, and investment.

Armory Square Ventures (ASV) is a venture capital firm based in Skaneateles, New York, founded in 2013 by Somak Chattopadhyay. The firm focuses on early-stage investments, particularly in the Seed and Series A stages, and emphasizes B2B software and technology-enabled services. ASV's primary investment regions include New York State and secondary markets across the Midwest. ASV is known for supporting transformative companies in underserved areas, aiming to revitalize local economies by backing high-growth startups. They have a robust portfolio that includes notable companies like BentoBox, RealEats, and ACV Auctions. ASV typically invests up to $1 million initially, with a strong commitment to follow-on investments, ensuring that startups have the necessary resources to scale. The firm's mission is deeply rooted in fostering economic growth in regions that have traditionally been overlooked by conventional venture capital. They provide more than just capital, offering active counsel, mentorship, and access to a broad network of investors and industry partners. The team at ASV includes experienced professionals such as Neenah Jain (Chief Financial Officer & Partner) and Pia Sawhney (Partner), who work collaboratively to guide startups through various growth stages. ASV's approach is characterized by its hands-on involvement, helping founders with strategic decisions, talent acquisition, and customer development.

Array Ventures, founded in 2015 and based in San Francisco, focuses on early-stage investments in enterprise technology startups. The firm is led by Shruti Gandhi, who leverages her extensive background in software engineering and venture capital to support innovative companies. Array Ventures primarily invests in enterprise SaaS, data, AI, security, infrastructure, and cloud technologies. They typically invest between $250,000 to $2 million in pre-seed and seed rounds, aiming for 8-15% ownership in their portfolio companies. Notable investments by Array Ventures include Simility (acquired by PayPal), CasaOne, Blumira, MadStreet Den, Modal, and Uniform.dev. The firm has a strategic focus on founders with strong technical backgrounds who are leaving lucrative corporate jobs to tackle significant problems. They provide robust support to help these startups grow from initial stages to achieving significant ARR milestones. Array Ventures also has a global investment approach, backing companies that address worldwide markets, including notable investments in Indian and Israeli startups.

Arrington XRP Capital is a dynamic cryptocurrency hedge fund, known for its strategic investments in blockchain technology and digital assets. Founded by Michael Arrington, the former TechCrunch founder, the fund has a significant footprint in the crypto space, backing notable startups such as Nexo, ThunderCore, and Algofi. Their investment portfolio spans various sectors including decentralized finance (DeFi), gaming, and blockchain infrastructure, with companies like Palm Tree Crew, Sipher, and Tinyman showcasing their diverse interests. Arrington XRP Capital primarily focuses on early-stage ventures and Initial Coin Offerings (ICOs), favoring innovative blockchain projects that demonstrate strong potential for growth. The fund operates globally, with no strict geographic limitations, allowing it to capture opportunities across different markets. The investment strategy is rigorous and thoughtful, typically participating in funding rounds with multiple investors to diversify risk. They prefer projects with robust technical foundations and visionary teams, aiming to support the long-term development of the blockchain ecosystem. The fund's typical check size varies, but they are known for leading rounds and providing substantial backing to promising startups​.

Artesian Investments, founded in 2004 by Jeremy Colless, Matthew Clunies-Ross, and John McCartney, is a global alternative investment management firm specializing in venture capital, public and private debt, and impact investment strategies. Based in Sydney, the firm has expanded its reach with offices in Melbourne, Adelaide, Shanghai, Jakarta, Singapore, London, and New York​​. Artesian's notable investments include Instaclustr, PouchNATION, and Regrow Ag. They are particularly active in the Asia-Pacific region, managing over $1.22 billion in assets and boasting more than 600 startup investments​ (Artesian)​. Their investment strategy focuses on early-stage ventures across various sectors, including technology, agrifood, medtech, and AI. Artesian also offers a unique "Venture Capital as a Service" (VCaaS) platform, providing customized investment solutions to corporations, government, and family offices​. The firm places a strong emphasis on ESG (Environmental, Social, and Governance) criteria and impact investing, aiming to deliver sustainable returns while addressing critical global challenges. Artesian is a certified B Corp, underscoring their commitment to positive social and environmental impact. Key team members include Jeremy Colless (CEO), Matthew Clunies-Ross (CIO), and Luke Fay (Partner, Australian Venture Capital). Their diversified team spans multiple continents, bringing extensive expertise and a global perspective to their investment activities

Arthur Ventures, established in 2008 and headquartered in Minneapolis, Minnesota, focuses on investing in early-stage B2B software companies across the U.S. and Canada. They emphasize backing startups located outside Silicon Valley, promoting innovation and growth in diverse regions. Arthur Ventures' portfolio includes a variety of successful companies. Notable investments feature DataCamp, an online data science training platform; Protenus, which offers patient data protection; and ThreatLocker, a zero-trust endpoint security solution. Other significant portfolio companies include Jane.app, a practice management software for health and wellness clinics, and CertifID, a network management software company. The firm has made over 102 investments and has seen 18 exits, with companies like Ionic and TINYpulse achieving successful outcomes. Arthur Ventures focuses on sectors such as SaaS, cybersecurity, fintech, and healthcare IT, providing capital and strategic support to help early-stage companies grow and succeed.

ARTIS Ventures (AV) is a San Francisco-based venture capital firm founded in 2001 by Stuart Peterson, investing in category-defining companies at the intersection of technology, health, and biology. The firm coined and trademarked the term TechBio to describe this investment category, and has built one of the most distinctive track records in the space over more than two decades. Peterson is a Forbes Midas List honoree, recognized in large part for ARTIS's early bet on Stemcentrx. Additional partners include Austin Walne and Ameena El-Bibany. ARTIS leads rounds and deploys $250K to $25 million per investment — with a sweet spot around $10 million — at Seed and Series A stages across the United States, Canada, and Israel. With 84 investments to date, the portfolio spans YouTube, Palantir, Data Domain, Aruba Wireless Networks, Nimble Storage, Cohesity, Practice Fusion, Versa Networks, Excision BioTherapeutics, and Fabric Genomics. The firm invests across biotech, AI, software, health technology, and data analytics. ARTIS runs a structured TechBio Fellows program that embeds MDs, PhDs, and domain experts directly within the fund to work alongside the investment team and portfolio companies. This model bridges frontier science and venture investing in a concrete way: rather than relying on external advisors, the firm has built its own scientific talent pipeline inside the fund. The result is a portfolio company support infrastructure that is unusually deep for a venture firm of ARTIS's size.

Asahi Kasei Ventures — formally Asahi Kasei Corporate Venture Capital — is the CVC arm of Asahi Kasei Corporation, a diversified Japanese conglomerate with revenues exceeding $20 billion across its Materials, Homes, and Health Care divisions. Established in 2008 in Tokyo and operating from Silicon Valley since 2011, with additional offices in Menlo Park and Boston, the fund invests in innovative startups strategically aligned with Asahi Kasei's long-term business development. General Manager Takashi Morishita has guided the fund since inception, personally involved in investments in 30-plus startups. The firm has invested in 53-plus companies across the United States, Europe, China, and Japan, averaging two new investments annually. Checks range from $1 million to $10 million at seed through Series B stages. Focus areas include healthcare and digital health, advanced materials, IoT, clean technology, energy storage, hydrogen, and biopharmaceuticals. The most recent investment was in Glycomine at Series C in April 2025. The fund's Care for Earth investment framework extends the mandate to environmental startups in sustainability and carbon neutrality. Portfolio companies gain access to Asahi Kasei's extensive research capabilities, manufacturing infrastructure, and global commercial network — advantages that have resulted in multiple strategic collaborations and two acquisitions for the parent company. The fund's long-term orientation and corporate backing allow it to support companies through extended development cycles that financial-only investors may not sustain.

Asahi Medialab Ventures is a Tokyo-based corporate venture capital firm founded in April 2017, managing funds backed by The Asahi Shimbun — one of Japan's largest daily newspapers, founded in 1879 — and the Asahi Shimbun Group's television station companies. CEO and President Hiroshi Nozawa leads a team of two, overseeing a focused investment mandate across Japan and the United States. The firm launched its initial fund with ¥50 million in capital and subsequently raised its Asahi Medialab Ventures No. 2 fund in 2022. With 43 investments at seed through Series A stages, Asahi Medialab deploys $500K to $3 million per deal across media and entertainment, software, food and beverage, sports, and lifestyle technology. Notable portfolio companies include GameOn Inc., East Meet East Inc., Snaq.me, PostCoffee, Pixellot, and Ai Robotics. The firm has achieved four portfolio exits, with Ai Robotics exiting in September 2024. The most recent investment was in Share-Me at seed stage in January 2026. The fund's principal advantage is its parent company's media ecosystem: portfolio companies gain potential access to Asahi Shimbun's editorial relationships, television distribution, digital platforms, and the broader Asahi Group network of content and commercial partnerships. For consumer technology and media startups seeking distribution in Japan — one of the world's largest and most media-sophisticated markets — this access is a significant commercial accelerant that financial investors alone cannot provide.

Ascend Venture Capital, founded in 2015 and headquartered in St. Louis, Missouri, is a beacon of innovation in the Midwest venture capital landscape. The fund primarily invests in early-stage startups across a variety of sectors including AI/ML, SaaS, and commercial products. Notable portfolio companies include Vouched, WhyLabs, and Yoodli, showcasing their commitment to cutting-edge technology and impactful solutions. With a strategic focus on the Midwest, Ascend aims to demonstrate that top-tier venture capital doesn't need to be confined to the coasts. Their investment strategy involves rigorous due diligence and a methodical approach akin to clinical trials. Ascend's first fund aimed to validate their investment thesis, while subsequent funds have stress-tested their systems and expanded their team. The average check size is around $2 million, and they participate in approximately six investment rounds annually. Ascend often uses special purpose vehicles (SPVs) to amplify investments in high-potential portfolio companies, particularly during critical Series A and B stages. The team is led by Dan Conner, the founding general partner, and Yinka Faleti, a key partner, both based in St. Louis. They emphasize human-centered values and transparency, fostering strong, genuine relationships with portfolio companies and investors alike. Ascend’s disciplined approach and focus on integrity and inclusivity have positioned them as a leading venture capital firm in the Midwest​.

Ascent Energy Ventures is a Denver-based venture capital firm focused on the digital transformation of the energy industry. Founded in 2019 by David Forsberg, the firm specializes in late-seed to early Series A investments, targeting startups that leverage digital tools to address modern energy challenges. Ascent’s portfolio emphasizes innovations in sectors like IoT, SaaS, advanced materials, and energy technology, focusing on companies that have demonstrated revenue traction and product-market fit. The firm's strategy centers on identifying and supporting entrepreneurs who apply advanced digital solutions to optimize energy operations, infrastructure, and sustainability. Notable investments include Galatea Technologies, a software firm, and Iron-IQ, a leader in industrial IoT for energy operations. Ascent looks for companies positioned for growth and profitability, often targeting those on the verge of significant scaling. In 2024, Ascent raised $12 million in seed funding to bolster its energy tech portfolio. Led by a team with extensive experience in energy investment and technology, Ascent provides both financial backing and strategic guidance. Key team members include Jim Newell, with over 20 years of venture investment experience, and Chris Lang, who has a background in energy derivatives and advisory roles at major financial institutions. Ascent Energy Ventures is a crucial player in the evolving energy landscape, helping startups secure funding and navigate complex markets to achieve lasting impact..